Calcineurin antagonists in vulvar lichen sclerosus

Arch Gynecol Obstet. 2006 Aug;274(5):266-70. doi: 10.1007/s00404-006-0151-1. Epub 2006 Jul 8.

Abstract

Lichen sclerosus et atrophicus is a chronic inflammatory disorder that mainly affects girls of premenarchial age and women in their fifties. Besides the anogenital region, lichen sclerosus (LS) may also affect extragenital or mucosal areas. Symptoms include soreness and pruritus, but other less common symptoms are not rare. An increased activity of fibroblasts causes increased sclerosis of the affected skin. Latest studies have identified LS as a chronic inflammatory dermatosis. Auto-antibodies against the extracellular membrane protein-1 are present in up to 80% of the patients. Moreover, in the widely accepted therapy with potent corticosteroids promising results have been presented using calcineurin antagonists in the treatment of LS. An interdisciplinary management and a continued care of patients with LS will improve the clinical manifestations and quality of life.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Calcineurin Inhibitors*
  • Carcinoma, Squamous Cell / etiology
  • Female
  • Humans
  • Vulvar Lichen Sclerosus / diagnosis
  • Vulvar Lichen Sclerosus / drug therapy*
  • Vulvar Lichen Sclerosus / pathology

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Calcineurin Inhibitors